R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

Frederick L. Locke, Moffitt Cancer Center, Tampa, Florida, presents in this MEDtalk, the importance of shortening vein-to-vein time in patients treated with axicabtagene ciloleucel (real-world data) and the association of metabolic tumor volume and clinical outcome after second-line treatment with axicabtagene ciloleucel versus standard of care.